Status:
UNKNOWN
COMT on Aspirin Platelets Effects (CAPE)
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
Specific Aim I: Examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Plate...
Detailed Description
This is a randomized double-blinded, placebo controlled study. This study is designed to detect the variation in platelet function based on COMT variation and how these platelets respond to cancerous ...
Eligibility Criteria
Inclusion
- healthy, 18-40 years
Exclusion
- taking aspirin. Smoking, pregnancy, history of cancer of cardiovascular disease. Mental illness.
Key Trial Info
Start Date :
July 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03433586
Start Date
July 10 2020
End Date
April 30 2022
Last Update
June 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115